Rozlytrek (entrectinib) capsules

Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancerr (NSCLC) not previously treated with ROS1 inhibitors.

Home | (entrectinib) capsules

Rozlytrek 100 mg hard capsules Price In India and Overseas
Rozlytrek 100 mg hard capsules

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

Rozlytrek 100 mg hard capsules

ROZLYTREK is a prescription medicine used to treat: Adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an abnormal ROS1 gene.

ROZLYTREK is a prescription medicine used to treat: Adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an abnormal ROS1 gene.

In the US, entrectinib is indicated to treat patients whose cancers are ROS1-positive (have a specific genetic feature (biomarker). It is to be used in those with solid tumors that: -are caused by certain abnormal neurotrophic tyrosine receptor kinase (NTRK) genes, -and have spread or if surgery to remove their cancer is likely to cause severe complications, and -there is no acceptable treatment, or the cancer grew or spread on other treatment Entrectinib is not approved for use in those less than twelve years of age.

In the European Union, entrectinib as monotherapy is indicated for the treatment of adults and adolescents twelve years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. It is also indicated for the treatment of adults with ROS1 positive, advanced non small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.

Drug (Brand / Generic): Rozlytrek / entrectinib
Current Indications: non-small cell lung cancer (NSCLC)
Marketed by:: Roche Registration GmbH
Approval Date: 31/07/2020

Available as (Form & Strength):
Dosage forms and strengths of Rozlytrek (entrectinib).
Rozlytrek 100 mg hard capsules
Rozlytrek 200 mg hard capsules

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.